Drugs / WIV04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04510207 | Jul 2020 → Jun 2021 | COVID-19 | China National Biotec Group Company Limited | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WIV04 | “Participants were randomized to receive 1 of 2 inactivated vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose; n = 13 459) and HB02 (4 µg/dose; n = 13 465) strains or an...” PMID 34037666 ↗ Jul 2021 |
| Modality | Vaccine | “inactivated SARS-CoV-2 vaccines” NCT04510207 ↗ |
| Route | Intramuscular | “they received 2 intramuscular injections 21 days apart” PMID 34037666 ↗ Jul 2021 |